SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT04676607
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
6
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG:
SHR7390
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School